News - Biogen Idec, daclizumab

Filter

Current filters:

Biogen Idecdaclizumab

Popular Filters

New entrants to multiple sclerosis market will drive 10% pa growth through 2018

26-07-2013

The market for disease-modifying multiple sclerosis (MS) therapies will expand at an annual rate of 10%…

AbbVieAubagioBayerBiogen IdecBiotechnologydaclizumabGlobalLemtradaMarkets & MarketingNeurologicalocrelizumabPharmaceuticalRocheSanofiTecfidera

Biogen jumps on strong MS drug data: Sanofi’s Lemtrada significant improvement on Rebif

24-10-2011

US biotech firm Biogen Idec (Nasdaq: BIIB) saw its shares jump 6% to $107.53 last Friday, after the company…

AlemtuzumabBiogen IdecBiotechnologydaclizumabdimethyl fumarateGenzymeLemtradaNeurologicalPharmaceuticalResearchSanofi

Biogen Idec and Abbott MS drug candidate daclizumab positive in Ph IIb

10-08-2011

US biotech Biogen Idec (Nasdaq: BIIB) and health care giant Abbott Laboratories (NYSE: ABT ) have announced…

Abbott LaboratoriesBiogen IdecBiotechnologydaclizumabNeurologicalPharmaceuticalResearch

Back to top